Logo

Sandoz Launches Inclunox and Inclunox HP (biosimilar- enoxaparin sodium solution) in Canada

Share this
Sandoz Launches Inclunox and Inclunox HP (biosimilar- enoxaparin sodium solution) in Canada

Sandoz Launches Inclunox and Inclunox HP (biosimilar- enoxaparin sodium solution) in Canada

Shots:

  • The company expands its portfolio with the marketing of the 6th biosimilars in Canada. Inclunox and Inclunox HP (enoxaparin sodium solution for injection) is indicated for use in 6 indications of the reference Lovenox and Lovenox HP in oncology- immunology- and endocrinology
  • Sandoz Canada has completed the pCPA negotiations for Inclunox and Inclunox HP- which is the first step in securing public reimbursement. The INESSS recommends that new biosimilar be listed on the List of Medications
  • Inclunox (IV or SC) is an anticoagulant biosimilar and is available in multiple prefilled syringes. Health Canada has authorized Lovenox and Lovenox HP on Nov 05- 2020 for marketing in Canada

Ref: Sandoz| Image: Sandoz

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions